Who
Christopher R. Cline
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Travere Therapeutics.
In numbers
- Trades disclosed
- 77
- Buys
- 0
- Sells
- 27
- Bought
- $0
- Sold
- $8.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Sep 2022
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $349K20,000 at $17.44 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M27,473 at $62.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M20,735 at $62.61 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K1,900 at $63.69 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K400 at $65.31 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $349K20,000 at $17.44 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.7M27,473 at $62.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M20,735 at $62.61 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $121K1,900 at $63.69 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K400 at $65.31 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $43K642 at $66.37 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $43K642 at $66.37 | filing |
| 6 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K310 at $43.95 | filing |
| 6 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K310 at $43.95 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K2,181 at $46.65 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K2,181 at $46.65 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,250 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Christopher R. Cline; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.